Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skeletal Responses to Ceredase in Type 1 Gaucher's Disease
NCT00001416Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Dec 1993
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alglucerase in Gaucher disease type 1 (GD1) (3 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoints: Decrease in hepatic volume at 24 months and Increase in trabecular bone density of the lumbar spine at 24 months. Started Dec 1993; status: completed.
02
Drugs
alglucerase
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NCT00001416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001416.